Understanding and predicting drug-drug interactions (DDIs) is crucial for ensuring patient safety and improving drug product development strategies. Not all pathways are created equally, however – the cytochrome P450 (CYP) enzyme family metabolizes the majority of marketed drugs, with many compounds also acting as perpetrators, making them a major source of clinically relevant DDIs. Join Dr. Viera Lukacova (Chief Science Officer, PBPK/CHEM Solutions) and Dr. Susie Zhang (Vice President, Regulatory Strategies) in this exclusive webinar as they outline a reliable, mechanistic PBPK modeling framework for predicting CYP enzyme-mediated DDIs with a high degree of confidence. Specifically, this webinar will provide practical strategies to help professionals identify, evaluate, and mitigate potential DDIs through modeling & simulation, ultimately ensuring drug product safety and supporting its regulatory approval.

What You Will Learn:

1. How to apply and interpret regulatory guidance and decision trees for evaluating CYP-mediated DDIs

2. The latest advancements using in vitro data and in silico tools for DDI prediction

3. Identification and integration of key clinical pharmacology information, including DDI data for more accurate risk assessment

4. The importance of high-quality DDI standard models and reports in providing validated, regulatory-aligned solutions

Who Should Attend?

This webinar is designed for regulatory professionals, clinical pharmacologists, drug development scientists, and anyone involved in assessing drug interactions and optimizing dosing strategies.

Interactive Q&A Session

Have questions? Ask your question live or submit them for a follow-up discussion.

Presenters:
Dr. Viera Lukacova – Chief Science Officer, PBPK/CHEM Solutions
Dr. Susie Zhang – Vice President, Regulatory Strategies

Moderator: 
Andrew Mueller, Director, Business Development

Don’t miss this opportunity to elevate your expertise in DDI risk assessment! Register now to secure your spot!